论文部分内容阅读
目的研究依诺肝素对急性冠脉综合征(acute coronary syndrome,ACS)患者血清抵抗素浓度的影响。方法选取2010年3月—2011年6月行冠状动脉造影的ACS患者93例,分为不稳定型心绞痛(unstable angina,UA)组34例、非ST段心肌梗死(non ST-segment elevation myocardial infarction,NSTEMI)组30例、ST段抬高性心肌梗死(ST-segment elevation myocardial infarction,STEMI)组29例,选择同期健康人30名作为对照组。所有患者给予依诺肝素皮下注射,收集治疗前后患者血液,经ELISA法测定血清抵抗素浓度,并进行组间比较。结果治疗后UA组、NSTEMI组、STEMI组血清抵抗素浓度分别为(8.15±1.18)、(15.21±12.03)、(15.08±2.20)μ/L,与治疗前比较,差异均有统计学意义,但仍均高于对照组(均P<0.05)。结论依诺肝素能显著降低ACS患者血清抵抗素浓度,抑制炎症反应,可减轻动脉粥样硬化。
Objective To investigate the effect of enoxaparin on serum resistin concentration in patients with acute coronary syndrome (ACS). Methods Ninety-three ACS patients undergoing coronary angiography from March 2010 to June 2011 were divided into unstable angina (UA) group (n = 34), non ST-segment elevation myocardial infarction , 30 cases of NSTEMI and 29 cases of ST-segment elevation myocardial infarction (STEMI) .30 healthy subjects were selected as the control group. All patients were given enoxaparin subcutaneously to collect the blood of patients before and after treatment, the concentration of serum resistin was measured by ELISA, and compared between groups. Results After treatment, the concentrations of serum resistin in UA group, NSTEMI group and STEMI group were (8.15 ± 1.18), (15.21 ± 12.03) and (15.08 ± 2.20) μ / L respectively, which were significantly different from those before treatment But still higher than the control group (all P <0.05). Conclusion Enoxaparin can significantly reduce the concentration of serum resistin in ACS patients, inhibit the inflammatory reaction and relieve atherosclerosis.